Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). AbCellera Biologics's share price for the quarter that ended in Mar. 2026 was $3.49. AbCellera Biologics's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 303.95 Mil. Therefore, AbCellera Biologics's market cap for the quarter that ended in Mar. 2026 was $1,060.77 Mil.
AbCellera Biologics's quarterly market cap
declined
from Sep. 2025 ($1,504.03 Mil) to Dec. 2025 ($1,028.06 Mil) but then
increased
from Dec. 2025 ($1,028.06 Mil) to Mar. 2026 ($1,060.77 Mil).
AbCellera Biologics's annual market cap
declined
from Dec. 2023 ($1,660.61 Mil) to Dec. 2024 ($866.57 Mil) but then
increased
from Dec. 2024 ($866.57 Mil) to Dec. 2025 ($1,028.06 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. AbCellera Biologics's Enterprise Value for Today is $1,889.12 Mil.
AbCellera Biologics (NAS:ABCL) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
AbCellera Biologics Market Cap Related Terms
AbCellera Biologics Market Cap Historical Data
* Premium members only.
The historical data trend for AbCellera Biologics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, AbCellera Biologics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AbCellera Biologics Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AbCellera Biologics's Market Cap distribution charts can be found below:
* The bar in red indicates where AbCellera Biologics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
AbCellera Biologics's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AbCellera Biologics (ABCL) has a Market Cap of $2,253.67 Mil as of Jun. 27, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on AbCellera Biologics and its competitors. According to the industry distribution chart, AbCellera Biologics ranks #160 out of 1431 companies in the Biotechnology industry, placing it in the top 11.2%.
Is AbCellera Biologics' Market Cap too high?
AbCellera Biologics' current Market Cap is $2,253.67 Mil. The Biotechnology industry median Market Cap is 113.83. AbCellera Biologics' value of $2,253.67 Mil is 1879.9% above this industry median. Based on the distribution chart, AbCellera Biologics ranks #160 out of 1431 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, AbCellera Biologics has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does AbCellera Biologics' Market Cap compare to SRPT and RAPP?
According to the Biotechnology industry distribution chart, AbCellera Biologics ranks #160 out of 1431 companies for Market Cap. This places AbCellera Biologics in the top 11% of its industry — outperforming the majority of peers. The industry median Market Cap is 113.83. AbCellera Biologics' value of $2,253.67 Mil is 1879.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 113.83, based on 1,431 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AbCellera Biologics's current Market Cap of $2,253.67 Mil is 1879.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on AbCellera Biologics and its competitors. For the Biotechnology industry, the median Market Cap is 113.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AbCellera Biologics's current Market Cap is $2,253.67 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AbCellera Biologics stock overvalued right now?
Based on GuruFocus' analysis, AbCellera Biologics (ABCL) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.62, compared to a current price of $7.38 — trading 31.3% above its estimated fair value. The current Market Cap is $2,253.67 Mil and 1879.9% above the Biotechnology industry median of 113.83. AbCellera Biologics' overall GF Score™ is 59/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For AbCellera Biologics (ABCL), the current Market Cap is $2,253.67 Mil as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AbCellera Biologics (ABCL) Overvalued in 2026?
Based on GuruFocus' analysis, AbCellera Biologics stock appears to be overvalued.
The current stock price of $7.38 is trading 31.3% above its estimated GF Value™ of $5.62.
GuruFocus considers AbCellera Biologics to be Significantly Overvalued.
Key valuation signals for ABCL:
Market Cap: $2,253.67 Mil
GF Value™: $5.62 vs. price of $7.38 (31.3% above fair value)
Industry Position: 1879.9% above the Biotechnology median (#160 of 1431)
No single metric tells the full story. See the ABCL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.
59GF Score
Get the complete analysis for ABCL
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ABCL has been successfully added to your 
